CytoSorbents regains Nasdaq minimum bid price compliance

Cytosorbents Corp

Received Nasdaq letter on July 26, 2024 confirming compliance after closing bid price at $1.00+ for 10 consecutive days through July 25.
Previously, on May 22, 2024, Nasdaq notified CytoSorbents of non-compliance due to bid price below $1.00 for 30 consecutive days.
Compliance had to be achieved by November 16, 2024; the company regained compliance early from July 12 to July 25.
CEO Dr. Phillip Chan stated the company is now in full compliance, strengthening its position ahead of expected DrugSorb-ATR regulatory submissions.
CytoSorbents continues aggressive cost cutting and operational progress on clinical, regulatory, and manufacturing fronts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.